Cardiogen Peptide 20mg

Description

What Is Cardiogen Peptide?

Cardiogen peptide is a synthetic tetrapeptide bioregulator with the amino acid sequence Ala-Glu-Asp-Arg (AEDR), developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. Cardiogen targets cardiac muscle tissue, functioning as a heart bioregulator that modulates gene expression in cardiomyocytes, cardiac fibroblasts, and supporting cardiovascular tissue. It belongs to the Khavinson bioregulator peptides class — short regulatory peptides that exhibit tissue-specific gene expression modulation at physiological concentrations — and has been studied in preclinical models of age-related cardiovascular decline, myocardial remodeling, and cardiac aging.

Cardiovascular disease remains the leading cause of age-related morbidity and mortality worldwide, yet the underlying epigenetic mechanisms of cardiac aging are only beginning to be understood. Cardiogen addresses this critical research gap by operating at the gene-expression level in cardiac tissue, offering a fundamentally different research approach compared to receptor agonists or hemodynamic modulators. Among the Khavinson bioregulator peptides, cardiogen is uniquely tissue-specific to the heart, making it the primary cardiac bioregulator peptide for cardiovascular aging research. PrymaLab Cardiogen 20mg is manufactured to high purity standards and supplied exclusively for qualified preclinical research.

Cardiogen 20mg: Key Specifications

How Does Cardiogen Peptide Work?

Epigenetic Gene Expression Modulation in Cardiac Tissue

Cardiogen operates through the peptide-DNA interaction mechanism characterized by Professor Khavinson’s research group, wherein short regulatory peptides selectively bind specific DNA sequences within gene promoter regions and alter chromatin conformation. In cardiac tissue, cardiogen modulates the expression of genes governing cardiomyocyte function, extracellular matrix homeostasis, mitochondrial bioenergetics, and intercellular signaling. This epigenetic mechanism operates at physiologically relevant concentrations, distinguishing bioregulator peptides from pharmacological agents that require supraphysiological doses.

Cardiac-Specific Tissue Targeting

The tissue specificity of cardiogen peptide derives from the selective affinity of the AEDR sequence for regulatory DNA motifs enriched in cardiac gene promoters. Preclinical studies have demonstrated that cardiogen preferentially modulates gene expression in cardiomyocytes and cardiac fibroblasts while exhibiting minimal transcriptional activity in non-cardiac cell types. This targeted activity profile makes cardiogen a valuable research tool for isolating cardiac-specific aging mechanisms from systemic cardiovascular changes.

Myocardial Homeostasis and Remodeling

Age-related cardiac decline involves progressive cardiomyocyte loss, compensatory hypertrophy, fibrotic remodeling, and diminished contractile reserve. Cardiogen research targets these processes at their transcriptional origin. Preclinical models show modulation of collagen deposition genes, anti-apoptotic signaling in cardiomyocytes, mitochondrial biogenesis factors, and calcium handling proteins — all critical components of the cardiac aging cascade that determine the trajectory from healthy to pathological cardiac remodeling.

Cardiogen Peptide Benefits Reported in Preclinical Research

Published studies on cardiogen peptide benefits report multiple tissue-specific effects relevant to cardiac aging and cardiovascular research applications. All findings described below are from preclinical animal and cell culture models.

Anti-Fibrotic Effects in Cardiac Tissue

Cardiac fibrosis is one of the most significant contributors to age-related heart failure, reducing myocardial compliance and impairing diastolic function. Cardiogen has demonstrated dose-dependent suppression of fibrotic gene expression in preclinical cardiac models, including reduced collagen type I and type III deposition, decreased transforming growth factor beta (TGF-β) signaling, and restored matrix metalloproteinase balance. These anti-fibrotic effects position cardiogen as a unique research compound for studying the reversibility of age-related cardiac stiffening.

Cardiomyocyte Survival and Anti-Apoptotic Signaling

The adult heart has extremely limited regenerative capacity, making cardiomyocyte preservation critical to cardiac longevity. Cardiogen research has shown upregulation of anti-apoptotic gene expression (including Bcl-2 family members) and enhanced cellular stress resistance in aged cardiomyocyte cultures. These findings suggest that cardiogen may help maintain functional cardiomyocyte populations during aging by shifting the balance from pro-apoptotic to pro-survival transcriptional programs.

Mitochondrial Bioenergetics in Cardiac Muscle

Cardiac muscle is the most mitochondria-dense tissue in the body, and age-related mitochondrial dysfunction directly impairs contractile function. Among the reported cardiogen benefits, restoration of mitochondrial biogenesis markers (PGC-1α, TFAM) and improved oxidative phosphorylation efficiency in aged cardiac tissue have particular significance for understanding the bioenergetic basis of cardiac aging.

Contractile Function and Calcium Handling

Preclinical cardiogen studies report improved contractile parameters in aged cardiac preparations, correlated with enhanced expression of calcium handling proteins including SERCA2a and ryanodine receptor regulatory subunits. These molecular findings provide mechanistic insight into how gene expression modulation at the epigenetic level can translate into measurable functional improvements in cardiac tissue.

Cardiovascular Anti-Aging Effects

Longitudinal animal studies by the Khavinson group have reported that cardiogen administration is associated with maintained cardiac function, reduced age-related structural remodeling, and preserved electrocardiographic parameters in aged cohorts compared to controls. These cardiovascular anti-aging observations form the foundation of ongoing bioregulatory gerontology research into cardiac lifespan extension.

Cardiogen Peptide Dosage in Research Applications

Published research provides context for cardiogen peptide dosage parameters across different experimental paradigms. The following represents reported dosage ranges from preclinical literature and is intended solely to inform research protocol design.

Important: These are reported research dosages from published preclinical literature. Optimal dosing depends on experimental design, animal model, route of administration, and research objectives. This product is not intended for therapeutic use.

Cardiogen vs. Vesilute: Cardiovascular Bioregulator Comparison

Researchers studying cardiovascular aging often compare cardiogen and vesilute because both target the cardiovascular system but through distinct tissue-specific mechanisms. Understanding their complementary roles is essential for designing comprehensive cardiovascular bioregulator research protocols.

The cardiogen-vesilute combination represents the most comprehensive cardiovascular bioregulator research approach in the Khavinson system, with cardiogen addressing the muscular pump (myocardium) and vesilute addressing the conduit system (vasculature). Researchers investigating systemic cardiovascular aging may benefit from protocols incorporating both peptides to capture the full spectrum of age-related cardiovascular tissue changes.

How to Store and Handle PrymaLab Cardiogen 20mg

1. Store lyophilized at −20°C. Keep sealed, desiccated, and protected from light. Stable for 24+ months.
2. Allow vial to reach room temperature before opening to prevent condensation.
3. Reconstitute with appropriate sterile solvent. Add slowly along vial wall.
4. Use reconstituted solution within 2–4 weeks. Refrigerate at 2–8°C.
5. Avoid repeated freeze-thaw cycles. Aliquot into single-use portions.
6. Retain the Certificate of Analysis for lot traceability.

Why Choose PrymaLab Cardiogen 20mg?

PrymaLab supplies Cardiogen 20mg as a high-purity research-grade heart bioregulator peptide verified at ≥98% purity by reverse-phase HPLC and identity-confirmed by mass spectrometry. Each batch ships with a unique lot number and Certificate of Analysis. Independent third-party testing ensures unbiased quality verification and full traceability for GLP-compliant cardiovascular research.

Frequently Asked Questions About Cardiogen Peptide

What is cardiogen peptide and what does it target?

Cardiogen is a synthetic tetrapeptide bioregulator (Ala-Glu-Asp-Arg, AEDR) developed by Professor Khavinson targeting cardiac muscle tissue. It modulates gene expression in cardiomyocytes, cardiac fibroblasts, and supporting heart tissue. Research applications include cardiac aging, myocardial remodeling, fibrosis, and cardiovascular anti-aging in preclinical models.

What are the reported cardiogen peptide benefits in research?

Published preclinical research reports cardiogen peptide benefits including anti-fibrotic effects in cardiac tissue (reduced collagen deposition, decreased TGF-β signaling), enhanced cardiomyocyte survival through anti-apoptotic gene upregulation, improved mitochondrial bioenergetics (PGC-1α, TFAM restoration), enhanced calcium handling and contractile function, and maintained cardiac structure in longitudinal aging models. All reported benefits are from preclinical research.

How does cardiogen differ from conventional cardioprotective compounds?

Cardiogen operates through epigenetic gene expression modulation in cardiac tissue rather than receptor agonism, enzyme inhibition, or hemodynamic modulation. This means it targets the transcriptional programs governing heart function rather than acutely modifying cardiac physiology. Among Khavinson bioregulator peptides, cardiogen provides direct myocardial effects complementary to vesilute’s vascular endothelial bioregulation.

What is the recommended cardiogen dosage for research?

Published cardiogen dosage ranges include 10–100 nM for cell culture studies and 1–10 µg/kg for in vivo aging models. Dosing depends on experimental design, model system, and research objectives. This product is for preclinical research only and is not intended for therapeutic dosing.

How should cardiogen be stored?

Store lyophilized cardiogen at −20°C, desiccated and protected from light, for 24+ months stability. After reconstitution, store at 2–8°C and use within 2–4 weeks. Aliquot to avoid freeze-thaw cycles.

Research Disclaimer

For Research Use Only. PrymaLab Cardiogen 20mg is intended exclusively for qualified preclinical research use. This product is not intended for human consumption, therapeutic use, veterinary treatment, or any application outside controlled research environments. Cardiogen has not been approved by the FDA or any equivalent regulatory authority for therapeutic use. All research applications described are from published preclinical and gerontological literature. Researchers are responsible for regulatory compliance.